Ilinpru

Linagliptin, the active ingredient in Ilinpru, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used in combination with diet and exercise.

GNH USA supplies Ilinpru as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including Europe and other regulated markets, with a focus on quality assurance and timely reliable logistics.

Ilinpru, a DPP‑4 inhibitor, is used in the treatment of type 2 diabetes mellitus to improve glycaemic control.

- Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): enhances overall glycaemic control when metformin alone is insufficient. - Type 2 diabetes mellitus (combined with insulin or other agents): provides additional glucose‑lowering effect in patients requiring multi‑drug regimens.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient, mild to moderate intensity. - Upper respiratory tract infection: symptoms of cough and congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea or abdominal pain. - Skin rash: mild erythematous lesions.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Acute renal failure: rare but reported in vulnerable patients.

Before initiating therapy, consider the following precautions: - Renal impairment: no dose adjustment required, but monitor renal function regularly. - Hepatic impairment: use with caution and assess liver enzymes periodically. - Hypersensitivity: discontinue if signs of allergic reaction such as rash, swelling, or difficulty breathing occur. - Pregnancy: safety not established; avoid unless potential benefit outweighs risk. - Elderly patients: monitor for hypoglycaemia when used with insulin or sulfonylureas. - Store at room temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with several medications. Review the following interaction categories:

Major Interactions (Avoid): - Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure and risk of adverse effects. - Strong P‑gp inducers (e.g., rifampicin, phenytoin): may reduce linagliptin plasma levels, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. - Metformin: monitor renal function to avoid lactic acidosis. - Diuretics: may affect blood glucose control; observe glycaemic response. - Antihypertensives: watch for additive blood pressure effects. - NSAIDs: potential for renal function changes; assess kidney status.